UNSPSC 51171915: Pantoprazole

This classification denotes a proton pump inhibitor with the molecular formula C16H15F2N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D8TST4O562, chemically known as 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridyl)methyl)sulfinyl)benzimidazole but generally known as pantoprazole, which bears US NIH Compound Identifier 4679. European Medicines Agency schedules Pantoprazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09608MIG.

UNSPSC 51171915 Pantoprazole is a Commodity code for a specific pharmaceutical product, but recent state and local opportunities show minimal direct procurement of pantoprazole itself; instead, the code appears in procurement environments where pantoprazole is one item within larger pharmaceutical supply or health services contracting. The scope of work varies widely across issuing bodies—from drug testing and specimen collection services (where pantoprazole is not a primary focus) to multi-source generic pharmaceutical supply agreements covering hundreds of products, to exploratory direct-to-manufacturer prescription programs. State and local buyers using this code include county criminal justice departments, state health and human services commissions, and cooperative purchasing alliances spanning multiple jurisdictions.

Activity concentrates in Texas and Minnesota, with Texas Health and Human Services Commission issuing an RFI (HHS0017013) on March 27, 2026 (response deadline April 3, 2026) to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, and Collin County (Texas) posting RFP 2026-327 on July 9, 2026 (due July 23, 2026) for offender specimen collection and drug testing services under a $600,000 two-year contract commencing September 1, 2026. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish multi-award contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers with pricing due July 1, 2026. The code shows limited direct demand for pantoprazole as a standalone procurement line item; opportunities tagged with it typically represent broader pharmaceutical supply or health services contexts where the product may be one of hundreds of items or is incidental to the primary service being contracted.